Liver Cancer

Immunotherapeutic Suppresses Hepatitis-B-Associated Cancer in Mice

Published in Hepatitis Weekly, November 13th, 2000

Enzo Biochem, Inc., (ENZ), reported that in preclinical animal studies of the company's proprietary immune regulation product, EHT899, researchers in Israel had achieved complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice.

Enzo said that the studies may have significant potential application for treatment of liver and other cancers in humans.

The research results were presented in a paper delivered at a plenary session of the American Association for the Study of Liver Diseases meeting in Dallas, Texas. The study was conducted by researchers at the Liver Unit at the Hadassah University...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry